Nigeria’s federal government has taken a significant step toward addressing one of the country’s most persistent gaps in cancer care: access to radiotherapy.
President Bola Tinubu has given the go-ahead for the purchase of 35 additional linear accelerators, machines that use high-energy radiation beams to destroy cancerous cells, with delivery expected to roll out between 2027 and 2029.
The announcement came from Dr. Iziaq Salako, Minister of State for Health and Social Welfare, during a meeting in Abuja with members of the Global Advisory Council of the National Cancer Control Plan Technical Working Group.
Salako framed the procurement as a cornerstone of the National Cancer Control Plan 2026–2030, the government’s roadmap for tackling a disease burden that has long outpaced the country’s treatment infrastructure.
Nigeria’s shortage of radiotherapy equipment has been a well-documented bottleneck for cancer patients, many of whom face long waiting lists or must travel abroad for treatment that machines at home cannot provide.
The addition of 35 units represents a substantial expansion of capacity, though full impact will depend on how quickly the machines are installed and staffed once delivered.
The linear accelerator rollout is part of a broader infrastructure drive. Salako disclosed that six new cancer treatment centers are under development nationwide, three of which have already been completed, with construction continuing on the remaining trio.
Details on their locations and specializations were not spelled out in the briefing, but the centers are expected to serve as regional hubs for diagnosis and treatment once fully operational.
Beyond equipment and buildings, Salako emphasized a philosophical pivot in the government’s approach one that leans more heavily on stopping cancer before it starts rather than treating it after diagnosis.
“Prevention is better and cheaper than cure,” Salako said. “We are doing everything possible to expand routine immunization, broaden screening, and improve early detection.”
Central to that strategy is the integration of human papillomavirus (HPV) vaccination into Nigeria’s routine immunisation schedule, a measure targeted specifically at reducing cervical cancer rates, a disease that disproportionately affects women across sub-Saharan Africa, often diagnosed at late, less treatable stages.
Alongside vaccination, the government is widening access to cervical cancer screening, pushing selected screening services down to primary and secondary healthcare facilities so that detection no longer depends on patients reaching specialist urban hospitals.
The Abuja meeting also marked the launch of the Blood Cancer Consortium, a new platform intended to unite oncologists, researchers, and other stakeholders around improving the management of leukemia, lymphoma, and related conditions in Nigeria cancers that require distinct diagnostic and treatment pathways from solid tumors.
Permanent Secretary Daju Kachollom, who welcomed the visiting delegation, stressed that stronger collaboration among stakeholders would be essential to improving outcomes nationally.
That sentiment was echoed by Prof. Folakemi Odedina, chair of the National Cancer Control Plan Technical Working Group, who described the initiative as having drawn together Nigerian cancer specialists both at home and in the diaspora, alongside healthcare providers, researchers, patients, advocates, and international partners.
Odedina noted that the working group is also focused on strengthening the country’s cancer research capacity and building a more robust national system for oncology clinical trials, an area where Nigeria has historically lagged behind global peers.
She added that partnerships with leading international cancer institutions would help local institutions sharpen both their research output and their treatment capabilities.
The visit concluded with the signing of a formal strategic partnership between the Federal Ministry of Health and Social Welfare’s Technical Working Group and the Global Advisory Council, intended to underpin implementation of the national cancer agenda going forward.
Health officials involved in the initiative have also framed Nigeria’s challenge within a continental context: cancer remains a formidable global health burden, one felt especially acutely in Africa because of late-stage presentation, high mortality rates, thin infrastructure, workforce shortages, and constrained funding.
Whether the newly approved accelerators, the expanding centers, and the prevention push translate into measurably better survival rates will likely take years to assess, but the moves signal that cancer control has moved higher up Nigeria’s public health agenda than it has in the past.
WHAT YOU SHOULD KNOW
Nigeria’s approval of 35 new linear accelerators marks a major step toward closing the country’s long-standing radiotherapy gap, but the real story is the strategy behind it.
Rather than treating equipment as a standalone fix, the government is pairing this investment with expanded HPV vaccination, wider cervical cancer screening, new treatment centers, and stronger research partnerships.
Nigeria is finally shifting from a reactive, treatment-only approach to one centered on prevention and early detection, the single most cost-effective way to reduce cancer deaths. Whether this translates into real progress will depend on execution between now and 2029.
